2020 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2020 MDL multi-district litigation AbbVie AbbVie Inc. MDS myelodysplastic syndromes ALL acute lymphoblastic leukemia Mead Johnson Mead Johnson Nutrition Company Amgen Amgen Inc. Merck Merck & Co., Inc. Amylin Amylin Pharmaceuticals, Inc. MF myelofibrosis aNDA abbreviated New Drug Application MPM Malignant Pleural Mesothelioma AstraZeneca AstraZeneca PLC MSI-H high microsatellite instability BCMA B-cell maturation antigen MyoKardia MyoKardia, Inc. Biogen Biogen, Inc. NASH Non alcoholic steatohepatitis BLA Biologics License Application NAV net asset value CERCLA U.S. Comprehensive Environmental Response, Compensation and Liability Act Nektar Nektar Therapeutics Celgene Celgene Corporation NDA New Drug Application cGMP current Good Manufacturing Practices NKT natural killer T CML chronic myeloid leukemia NLRP3 NACHT, LRR and PYD domains-containing protein 3 CPPIB CPPIB Credit Europe S.A.R.L., a Luxembourg private limited liability company Novartis Novartis Pharmaceutical Corporation CRC colorectal cancer NSCLC non-small cell lung cancer DSA Distribution Services Agreement NVAF non-valvular atrial fibrillation EC European Commission OIG Office of Inspector General of the U.S. Department of Health and Human Services EGFR estimated glomerular filtration rate Ono Ono Pharmaceutical Co., Ltd. EMA European Medicines Agency OTC Over-the-counter EPO European Patent Office Otsuka Otsuka Pharmaceutical Co., Ltd. EPS earnings per share PBMs Pharmacy Benefit Managers ERISA Employee Retirement Income Security Act of 1974 PD-1 programmed death receptor-1 ESA erythoropoiesis-stimulating agent PDMA Prescription Drug Marketing Act ESCC esophageal squamous cell carcinoma Pfizer Pfizer, Inc. EU European Union PhRMA Code Pharmaceutical Research and Manufacturers of America’s Professional Practices Code FASB Financial Accounting Standards Board PRP potentially responsible party FCPA Foreign Corrupt Practices Act PsA psoriatic arthritis FDA U.S. Food and Drug Administration R&D research and development FL follicular lymphoma RA rheumatoid arthritis GAAP U.S. generally accepted accounting principles RCC renal cell carcinoma GBM glioblastoma multiforme RDP regulatory data protection Gilead Gilead Sciences, Inc. REMS Risk Evaluation and Mitigation Strategy GILTI global intangible low taxed income Roche Roche Holding AG GlaxoSmithKline GlaxoSmithKline PLC RRMM relapsed/refractory multiple myeloma GTN gross-to-net RS ring sideroblast Halozyme Halozyme Therapeutics, Inc. Sanofi Sanofi S.A. HCC Hepatocellular carcinoma sBLA supplemental Biologics License Application HIV human immunodeficiency virus SCCHN squamous cell carcinoma of the head and neck HR 3590 The Patient Protection and Affordable Care Act SCLC small cell lung cancer ImClone ImClone Systems Incorporated SEC U.S. Securities and Exchange Commission IO Immuno-Oncology STING stimulator of interferon genes IPF idiopathic pulmonary fibrosis the 2012 Plan The 2012 Stock Award and Incentive Plan IPRD in-process research and development the Act the Tax Cuts and Jobs Act of 2017 JIA Juvenile Idiopathic Arthritis U.S. United States LOE loss of exclusivity UK United Kingdom MAA Marketing Authorization Application VAT value added tax LIBOR London Interbank Offered Rate VTE venous thromboembolic Lilly Eli Lilly and Company WTO World Trade Organization MCOs Managed Care Organizations SUMMARY OF ABBREVIATED TERMS Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us in this 2020 Form 10-K, unless the context otherwise indicates. Throughout this 2020 Form 10-K, we have used terms which are defined below: 132